In this study, we aim to evaluate the causal impacts of the most commonly prescribed lipid-lowering drugs comprised of HMGCR, PCSK9, and NPC1L1 inhibitors on multiple sarcopenia-related traits via the MR approach and provide innovative recommendations for the clinical administration. This evidence concerns the gene HMGCR and sarcopenia.